Data / Drug companies / Contract Pharmacal Corp.
Contract Pharmacal Corp.: 26 products in the FDA NDC directory, labeler code 10267
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Contract Pharmacal Corp. (labeler code 10267) lists 26 products in the FDA National Drug Code Directory, covering 4 finished drugs by generic name. By type: 15 drugs for further processing, 7 prescription drugs. Its main marketing category is drugs for further processing. The newest product started marketing on April 16, 2025.
The request: Watch Contract Pharmacal Corp. (FDA labeler code 10267): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 10267
- Products in commercial distribution
- 26
- Packages
- 50
- Finished drugs by generic name
- 4
- Prescription products
- 7
- Over the counter products
- 4
- Flagged as original packager
- 11 of 11 products that carry the flag
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- October 16, 2009
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Drugs for further processing | 15 | 57.7% |
| Generic drugs (ANDA) | 11 | 42.3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Drugs for further processing | 15 | 57.7% |
| Prescription drugs | 7 | 26.9% |
| Over the counter drugs | 4 | 15.4% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Doxepin hydrochloride | 5 | 45 |
| Ibuprofen | 3 | 190 |
| Famotidine | 2 | 138 |
| Cetirizine hydrochloride 10 mg | 1 | 2 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 12 | 46.2% |
| Capsule | 6 | 23.1% |
| Tablet, chewable | 3 | 11.5% |
| Tablet | 3 | 11.5% |
| Tablet, coated | 2 | 7.7% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Tricyclic Antidepressant | 5 |
| Nonsteroidal Anti-inflammatory Drug | 3 |
| Histamine-2 Receptor Antagonist | 2 |
| Histamine-1 Receptor Antagonist | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Cetirizine Hydrochloride 10 mg | 10267-3579 | Tablet, film coated | Generic drugs (ANDA) | April 16, 2025 |
| Acetaminophen, caffeine | 10267-5808 | Tablet, film coated | Drugs for further processing | October 10, 2024 |
| Famotidine | 10267-5690 | Tablet, coated | Generic drugs (ANDA) | August 31, 2024 |
| Famotidine | 10267-5689 | Tablet, coated | Generic drugs (ANDA) | August 31, 2024 |
| Sennosides | 10267-0032 | Tablet, film coated | Drugs for further processing | November 30, 2023 |
| Acetaminophen | 10267-5923 | Tablet, film coated | Drugs for further processing | September 21, 2023 |
| Doxepin Hydrochloride | 10267-5063 | Capsule | Generic drugs (ANDA) | January 24, 2021 |
| Doxepin Hydrochloride | 10267-5062 | Capsule | Generic drugs (ANDA) | January 24, 2021 |
| Doxepin Hydrochloride | 10267-5061 | Capsule | Generic drugs (ANDA) | January 24, 2021 |
| Doxepin Hydrochloride | 10267-5060 | Capsule | Generic drugs (ANDA) | January 24, 2021 |
| Doxepin Hydrochloride | 10267-5059 | Capsule | Generic drugs (ANDA) | January 24, 2021 |
| Acetaminophen and pamabrom | 10267-5511 | Tablet, film coated | Drugs for further processing | October 29, 2019 |
| Magnesium salicylate, caffeine | 10267-5008 | Tablet, film coated | Drugs for further processing | October 11, 2017 |
| Acetaminophen, aspirin, caffeine | 10267-5005 | Tablet, film coated | Drugs for further processing | May 15, 2017 |
| Caffeine | 10267-5010 | Tablet, film coated | Drugs for further processing | May 4, 2017 |
| Sodium citrate | 10267-4243 | Tablet, chewable | Drugs for further processing | October 22, 2015 |
| Calcium polycarbophil | 10267-0339 | Tablet, film coated | Drugs for further processing | June 22, 2015 |
| Diphenhydramine hydrochloride | 10267-4690 | Capsule | Drugs for further processing | March 11, 2015 |
| Phenazopyridine hydrochloride | 10267-0317 | Tablet, film coated | Drugs for further processing | September 8, 2014 |
| Ibuprofen | 10267-3909 | Tablet | Generic drugs (ANDA) | January 15, 2014 |
| Ibuprofen | 10267-3852 | Tablet | Generic drugs (ANDA) | January 15, 2014 |
| Ibuprofen | 10267-3846 | Tablet | Generic drugs (ANDA) | January 15, 2014 |
| Pamabrom | 10267-0687 | Tablet, film coated | Drugs for further processing | August 26, 2013 |
| Dimenhydrinate | 10267-4186 | Tablet, chewable | Drugs for further processing | July 19, 2012 |
| Dimenhydrinate | 10267-4215 | Tablet, chewable | Drugs for further processing | January 20, 2012 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.